Cardiac risk dashes testosterone hopes in ageing men

The limited health benefits of testosterone need to be weighed against increased cardiac risk in ageing men with low levels of the hormone, according to the largest trials to date of the controversial therapy.

On Wednesday, the Journal of the American Medical Assocation published results from a group of studies, known as the Testosterone Trials (T Trials), on 12-month outcomes of transdermal testosterone gel (T gel) treatment of men aged 65 and older.

The researchers, funded by the US National Institutes of Health,